NasdaqGM:ETNBBiotechs
Regulatory Progress and Production Scale-Up Might Change the Case for Investing in 89bio (ETNB)
89bio, Inc. recently announced its second quarter 2025 earnings results, reporting a net loss of US$111.5 million and providing updates on its late-stage clinical programs for pegozafermin targeting MASH and severe hypertriglyceridemia.
An important development is the company’s alignment with the FDA and EMA for accelerated approval pathways and ongoing progress in scaling up commercial production capacity.
We’ll explore how updates on pegozafermin’s clinical trial timelines and regulatory...